PARIS, July 12, 2017 /PRNewswire/
--
ENTEROME SA, a pioneer of innovative
therapies for microbiome-related diseases, is pleased to announce
that Mary Thistle has joined the
Enterome board as a Non-executive Director.
Ms. Thistle brings extensive experience in the life sciences
industry, serving in senior finance, operations and business
development roles. She is currently Chief Operating Officer at
Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical
company discovering and developing new therapeutic products for
people living with devastating rare and metabolic diseases
associated with the liver, based on the most advanced mammalian
adeno-associated virus (AAV) gene delivery technology.
Prior to joining Dimension in 2015, Ms. Thistle was Senior Vice
President, Business Development at Cubist Pharmaceuticals, where
she was responsible for four major acquisitions, including Trius
Therapeutics and Optimer Pharmaceuticals, significantly driving
growth of the company's pipeline prior to Cubist's $9.5 billion acquisition by Merck & Co. (MSD
outside the US). Prior to this, she held leadership positions at
ViaCell, Inc. Ms. Thistle began her career in finance as a
certified public accountant working with both private and public
companies. She received her B.A. degree in accounting from the
University of Massachusetts.
Georges Gemayel, Non-executive
Chairman of Enterome, said: "We are pleased to welcome Mary to the
Enterome Board. This is an exciting period for the Company and we
are confident that Mary's experience will be a valuable asset
assisting us to achieve our goals."
Ms. Thistle added: "I am honoured to join the Enterome board and
look forward to working with the management team to help the
Company capitalize on its world-leading position in understanding
the microbiome to create novel therapies for microbiome-related
diseases."
A photo is available on request.
About Enterome
Enterome is pioneering the development of novel pharmaceuticals
and diagnostics to support personalized therapies in
microbiome-related diseases such as Inflammatory Bowel Disease
(IBD), cancer and metabolic diseases.
Enterome is also leading the development of new industry
standards in gut microbiome quantitative and functional analysis.
This technology leadership allows Enterome to open up the new field
of therapeutic target discovery in the microbiome in order to
address significant unmet medical needs.
Enterome has established partnerships with leading
pharmaceutical companies and academic research institutes,
including Johnson & Johnson Innovation/Janssen Biotech, Takeda
and Abbvie in inflammatory bowel and gastro-intestinal diseases;
Bristol-Myers Squibb in immuno-oncology; and the Mayo Clinic and
Geisinger hospitals in metabolic disorders.
Enterome also has a 50/50 joint venture with Nestlé Health
Science, called Microbiome Diagnostics Partners, focused initially
on the development of novel microbiome-based diagnostics for IBD
and liver diseases.
The Company was established in 2012 in Paris (France) to develop the discoveries made
by the INRA metagenomic platform, and is backed by leading venture
capital investors (Seventure Partners, Lundbeckfonden Ventures,
Health for Life Capital & Omnes Capital) and strategic
investors (Nestlé Health Science, Shire & INRA Transfert).
Additional information about Enterome is available through its
website: www.enterome.com
